908 Devices Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing reports annual results, with 2021 as the principal comparable period.
Business context
908 Devices develops handheld and desktop mass spectrometry devices for point-of-need chemical and biochemical analysis. Its products serve government and forensic users, pharmaceutical and biotechnology customers, and academic institutions. The MX908 is its primary handheld product; desktop offerings include Rebel and ZipChip. The company acquired TRACE Analytics GmbH in August 2022, adding online bioprocess sampling and monitoring technology. Maven launched in January 2023.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $46.9 million | $42.2 million |
| Gross profit | $26.0 million | $23.2 million |
| Net loss | $33.6 million | $22.2 million |
| Net loss per share, basic and diluted | $1.07 | $0.79 |
| Cash used in operating activities | $20.9 million | $29.1 million |
| Cash used in investing activities | $15.8 million | $0.7 million |
| Cash provided by financing activities | $1.2 million | $94.7 million |
At December 31, 2022, cash and cash equivalents were $188.4 million, total assets were $242.6 million, and total liabilities were $52.0 million. The balance sheet showed $15.0 million of long-term debt; that borrowing was repaid in full on January 4, 2023. The company reported an accumulated deficit of $134.2 million.
Changes versus FY2021
- Revenue grew 11% to $46.9 million. Product and service revenue rose 8% to $44.5 million, while license and contract revenue increased 116% to $2.4 million.
- Device sales fell 14% to $28.8 million, chiefly because 122 fewer MX908 units were sold, including lower shipments to the U.S. Army. Consumables and service revenue more than doubled to $15.7 million, up 101%.
- Product and service gross margin edged down to 54% from 55%. Total operating expenses rose 36% to $61.4 million, including R&D expense of $17.5 million and selling, general and administrative expense of $43.9 million. The net loss widened by $11.4 million.
- Operating cash use improved by $8.2 million. Investing cash use increased mainly because of the Trace acquisition, which used $13.8 million net of cash acquired. Financing cash flow was substantially lower than in 2021, when the company raised $94.8 million net from a public offering.
- Recurring consumables and service revenue increased to 35% of product and service revenue from 19%. Total product placements declined to 450 from 574; cumulative placements reached 2,385.
Outlook, risks and unusual items
- Management expects continuing losses while investing in sales, manufacturing, R&D, and product development. It said existing cash and cash equivalents were expected to fund operating expenses, capital expenditures, and debt service for at least 12 months; this assessment depends on assumptions that may not hold. No quantified revenue or earnings guidance is provided in the filing.
- On March 10, 2023, Silicon Valley Bank (SVB) was closed; Signature Bank was closed on March 12. The company disclosed that substantially all its cash and cash equivalents were held at these institutions. Following government announcements, management expected access to all deposits and said it did not expect the closures to impair its ability to operate for at least 12 months. Access to the undrawn SVB revolver remained subject to covenant compliance and SVB’s ability to perform.
- The $35 million SVB revolving facility had $15 million drawn at year-end and was repaid in January 2023. Its covenants include a minimum liquidity test and limits on non-SVB deposits, among other restrictions.
- Trace’s acquisition carried stated potential consideration of $17.3 million, including $14.4 million upfront, up to $2.0 million in milestone payments, and a $0.9 million pension-liability holdback. The purchase-price allocation was preliminary at year-end. Trace contributed $0.8 million of revenue after acquisition through year-end.
- Risks include persistent losses and cash burn; long, variable sales cycles; dependence on government spending and a limited number of large orders; customer and distributor concentration; competition; reliance on some single-source suppliers; execution and integration of new products and Trace; and export, regulatory, intellectual-property, and cybersecurity risks. One customer accounted for 28% of FY2022 revenue.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not attest to internal control effectiveness because the company qualified for the emerging-growth-company exemption.
Investor facts to verify
- Confirm the post-year-end availability and location of cash following the SVB and Signature Bank closures, and the operational status and covenant conditions of the SVB revolver.
- Track whether recurring revenue growth and consumables usage can offset slower device placements, particularly lower MX908 sales.
- Assess the path to profitability against rising operating expenses, cash burn, and management’s stated 12-month liquidity outlook.
- Review Trace integration, milestone outcomes, and final purchase-price allocation, and assess commercial progress for Maven and other planned product expansions.
- Monitor government-customer concentration, distributor exposure, and supplier continuity; the filing identifies material dependence on major customers and certain single-source components.